Dyadic to present at industry events in november
Jupiter, fla., oct. 30, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of november: cultured meat symposium 2023, november 2-3, 2023starbase, las vegasjoseph hazelton, chief business officer 8th international vaccines research & development, november 6-8, 2023hilton baltimore bwi airport hotel, linthicum heights, mdmark emalfarb, president, and chief executive officer “next-gen vaccines without the right platform limit pandemic effectiveness c1, protective, rapid, high yield, low-cost global solution” presentation time: monday, november 6, 2023, 2:10 pm – 2:30 pm et barda industry day 2023, november 13-14, 2023grand hyatt washington, washington, dcjoseph hazelton, chief business officer vaccines summit, november 13-15, 2023sheraton boston needham hotel, boston, mamark emalfarb, president, and chief executive officer “rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including covid-19 and seasonal and pandemic influenza” presentation time: wednesday, november 15, 2023, 1:40 pm – 2:00 pm et if you would like to connect with dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com about dyadic international, inc. dyadic international, inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.
